[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354143-105":59,"doc-detail-354143-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dnmt1-duoxa1-axis-discovers-a-novel-methylation-ferroptosis-circuit-in-bicalutamide-resistant-prostate-cancer","DNMT1-DUOXA1 axis discovers a novel methylation-ferroptosis circuit in bicalutamide-resistant prostate cancer","","Prostate cancer is a prevalent malignancy in the male reproductive system, and bicalutamide resistance remains a key therapeutic obstacle. This study reports a non-AR-dependent resistance mechanism centered on DUOXA1, a maturation factor for dual oxidases that produces H2O2. RNA-seq analysis identifies DUOXA1 downregulation in resistant cells. Hypoxia elevates HIF1α transcriptional activity, increasing DNMT1 expression. DNMT1 methylates the DUOXA1 promoter, silencing DUOXA1 and suppressing ferroptosis through impaired iron metabolism and lipid peroxidation, ultimately promoting resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dnmt1-duoxa1-axis-discovers-a-novel-methylation-ferroptosis-circuit-in-bicalutamide-resistant-prostate-cancer/354143/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dnmt1-duoxa1-axis-discovers-a-novel-methylation-ferroptosis-circuit-in-bicalutamide-resistant-prostate-cancer/354143.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What non-AR-dependent mechanism of bicalutamide resistance does the study propose?","Question",{"text":112,"@type":113},"The study proposes that resistance is driven by an HIF1α-DNMT1-DUOXA1 epigenetic axis. Hypoxia increases HIF1α activity, which upregulates DNMT1 to methylate and silence the DUOXA1 promoter.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does DUOXA1 affect ferroptosis in bicalutamide-resistant prostate cancer?",{"text":117,"@type":113},"DUOXA1 promotes bicalutamide resistance by enhancing ferroptosis through ROS generation. When DUOXA1 is epigenetically silenced, ferroptosis is inhibited.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of DNMT1 in the methylation-ferroptosis circuit?",{"text":121,"@type":113},"DNMT1 acts as an epigenetic modifier that mediates DUOXA1 promoter methylation, silencing DUOXA1 expression and thereby blocking ferroptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354143,1790307321,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Redox Biology 94 (2026) 104188  \nContents lists available at ScienceDirect  \nRedox Biology  \njournal [homepage:](homepage: www.elsevier.com/locate/redox)[ www.elsevier.com/locate/redox](homepage: www.elsevier.com/locate/redox)  \n| DNMT1-DUOXA1 axis discovers a novel methylation-ferroptosis circuit in bicalutamide-resistant prostate cancer\u003Cbr>Shunyao Xiaa, Yan Sun b, Ziwen Yea, Haixing Jiac, Zan Liu a,*, Youcheng Xiua,** \u003Cbr>a First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China\u003Cbr>b The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China c Department of Urology, TEDA Hospital, Tianjin, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Prostate cancer Bicalutamide DUOXA1\u003Cbr>Epigenetic modification Ferroptosis |  | Prostate cancer, a prevalent malignancy in the male reproductive system, poses significant therapeutic challenges due to the development of resistance to androgen deprivation therapies such as bicalutamide. While current research predominantly focuses on androgen receptor (AR)-dependent mechanisms of resistance, non-ARdependent pathways remain poorly understood. Here, we report a novel non-AR-dependent mechanism ofbicalutamide resistance centered on DUOXA1, a maturation factor for dual oxidases (DUOX) that catalyzes hydrogen peroxide (H2O2) production. Our analysis of RNA sequencing data from bicalutamide-resistant and sensitive prostate cancer cells revealed DUOXA1 as a significantly downregulated gene in resistant cells. We demonstrate that hypoxia in the prostate cancer microenvironment enhances HIF1α transcriptional activity, leading to increased DNMT1 expression. DNMT1, an epigenetic modifier, mediates the methylation of the DUOXA1 promoter, thereby silencing its expression. This epigenetic silencing of DUOXA1 inhibits ferroptosis, a form of regulated cell death characterized by iron metabolism disruption and lipid peroxidation, thereby promoting bicalutamide resistance. Our findings indicate that DUOXA1 can enhance bicalutamide resistance by promoting ferroptosis through ROS generation. This study not only provides mechanistic insights into the role of DUOXA1 in bicalutamide resistance but also highlights the HIF1α-DNMT1-DUOXA1 axis as a critical regulator of resistance. Our work suggests potential therapeutic strategies to overcome resistance through epigenetic modulation and activation of DUOXA1, offering a novel perspective on the molecular mechanisms of bicalutamide resistance and paving the way for the development of improved treatment approaches for advanced prostate cancer. |\n\n1. Introduction  \nProstate cancer is one of the most common malignancies in the male reproductive system, with a particularly high incidence in elderly men [1]. Androgen stimulation accelerates cancer cell growth and metastasis, making androgen deprivation therapy a cornerstone of treatment [2,3]. Bicalutamide, a nonsteroidal anti-androgen, competitively binds to androgen receptors (AR), blocking endogenous androgens such as dihydrotestosterone (DHT) and reducing tumor progression [4,5]. However, the development of bicalutamide resistance remains a significant clinical challenge in the treatment of prostate cancer [6]. Current research efforts have predominantly focused on AR-dependent mechanisms, such as AR gene amplification [7], mutations (e.g., T878A,  \nW742L), and splice variants (e.g., AR-V7) [8], which contribute to ligand-independent AR activation. However, non-AR-dependent pathways remain poorly understood. Further investigation into both AR and non-AR-mediated resistance is essential to identify novel targets and overcome treatment limitations in advanced disease.  \nEmerging evidence indicates that estrogen receptor α (ERα) promotes bicalutamide resistance through NRF2-mediated activation of antioxidant defense systems, consequently suppressing ferroptotic cell death [9]. Notably, preclinical studies suggest that ","cbCail3JTvB5w6fi","https://ap.wps.com/l/cbCail3JTvB5w6fi","pdf",15120927,14,"English","# Introduction\n## Androgen deprivation therapy and bicalutamide resistance\n## Non-AR-dependent mechanisms and ferroptosis\n## Study rationale and prior evidence","[{\"question\":\"What non-AR-dependent mechanism of bicalutamide resistance does the study propose?\",\"answer\":\"The study proposes that resistance is driven by an HIF1α-DNMT1-DUOXA1 epigenetic axis. Hypoxia increases HIF1α activity, which upregulates DNMT1 to methylate and silence the DUOXA1 promoter.\"},{\"question\":\"How does DUOXA1 affect ferroptosis in bicalutamide-resistant prostate cancer?\",\"answer\":\"DUOXA1 promotes bicalutamide resistance by enhancing ferroptosis through ROS generation. When DUOXA1 is epigenetically silenced, ferroptosis is inhibited.\"},{\"question\":\"What is the role of DNMT1 in the methylation-ferroptosis circuit?\",\"answer\":\"DNMT1 acts as an epigenetic modifier that mediates DUOXA1 promoter methylation, silencing DUOXA1 expression and thereby blocking ferroptosis.\"}]","DNMT1-DUOXA1 axis discovers a novel methylation-ferroptosis circuit in bicalutamide-resistant prostate cancer | PDF",1790109221,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ca397f1bad27c8ab4831082257ae70d.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a08ccf7f2eac87e0aa4fbbc286e1762f.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a68da24487ba7371faf72239ca1cd9c6.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56a6cc4e976a83540221232006c3fcb4.webp",980,1306]